Immunome, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||
| Net Income | $-212.4M | $-293.0M | $-106.8M | $-36.9M | $-24.7M | $-17.8M | $-10.4M |
| Depreciation & Amortization | $2.5M | $1.6M | $457.0K | $422.0K | $755.0K | $755.0K | $615.0K |
| Depreciation | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — |
| Stock-Based Compensation | $25.7M | $15.7M | $6.2M | $5.3M | $3.4M | $621.0K | $14.0K |
| Net Cash from Operating Activities | $-190.9M | $-110.8M | $-7.6M | $-28.7M | $-18.2M | $-12.1M | $-9.6M |
| Investing Activities | |||||||
| Capital Expenditures | $9.7M | $7.2M | $831.0K | $248.0K | $79.0K | $586.0K | $233.0K |
| Business Acquisitions | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $60.8M | $-85.1M | $-30.5M | $-248.0K | $-79.0K | $-586.0K | $-233.0K |
| Financing Activities | |||||||
| Dividends Paid | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $640.4M | $240.5M | $116.4M | $32.0K | $27.8M | $49.9M | $10.8M |
| Net Change in Cash | $510.2M | $44.7M | $78.4M | $-28.9M | $9.5M | $37.2M | $941.0K |
| Free Cash Flow | $-200.6M | $-118.0M | $-8.4M | $-28.9M | $-18.3M | $-12.7M | $-9.8M |